
    
      This study is a non-inferiority study comparing efficacy and onset of action between the
      herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac
      topical solution 1.5% (approved by the FDA as a topical analgesic). Approximately 168 Duke
      patients will be recruited from Duke Pain Clinic, and selected Duke primary care practices.
      Individuals who report acute (less than 3 months duration) or chronic musculoskeletal pain of
      any intensity will be considered for enrollment into the study. After obtaining consent,
      eligible subjects will be will be randomized to receive Bonipar or diclofenac topical
      solution 1.5%.
    
  